Avinger, Inc. (AVGR)
NASDAQ: AVGR · Real-Time Price · USD
0.797
-0.035 (-4.25%)
Dec 3, 2024, 11:45 AM EST - Market open

Company Description

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany.

The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists.

The company was incorporated in 2007 and is based in Redwood City, California.

Avinger, Inc.
Avinger logo
Country United States
Founded 2007
IPO Date Jan 30, 2015
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 72
CEO Jeffrey Soinski

Contact Details

Address:
400 Chesapeake Drive
Redwood City, California 94063
United States
Phone (650) 241-7900
Website avinger.com

Stock Details

Ticker Symbol AVGR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001506928
CUSIP Number 053734604
ISIN Number US0537348775
Employer ID 20-8873453
SIC Code 3841

Key Executives

Name Position
Himanshu N. Patel Chief Technology Officer
Keith Schaefer Chief Operating Officer
Philip R. Preuss Chief Commercial Officer
Dr. Jaafer Golzar FACC, M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 22, 2024 8-K Current Report
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 8-K Current Report
Nov 7, 2024 10-Q Quarterly Report
Nov 5, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 5, 2024 DEF 14A Other definitive proxy statements
Oct 18, 2024 8-K Current Report
Oct 17, 2024 424B5 Filing
Aug 12, 2024 8-K Current Report